IDEXX Laboratories, Inc. (IDXX) Shares Bought by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 270,239 shares of the company’s stock after acquiring an additional 3,212 shares during the period. IDEXX Laboratories makes up 1.2% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 12th largest position. Stephens Investment Management Group LLC’s holdings in IDEXX Laboratories were worth $60,425,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. Vanguard Group Inc raised its stake in shares of IDEXX Laboratories by 0.3% during the third quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock valued at $2,226,581,000 after purchasing an additional 23,970 shares during the period. BlackRock Inc. raised its holdings in IDEXX Laboratories by 4.6% during the 4th quarter. BlackRock Inc. now owns 6,549,022 shares of the company’s stock worth $1,218,251,000 after buying an additional 289,208 shares during the period. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 7.6% during the 4th quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock worth $215,959,000 after buying an additional 81,641 shares during the period. Northern Trust Corp raised its holdings in IDEXX Laboratories by 2.6% during the 4th quarter. Northern Trust Corp now owns 1,056,136 shares of the company’s stock worth $196,463,000 after buying an additional 26,522 shares during the period. Finally, MERIAN GLOBAL INVESTORS UK Ltd raised its holdings in IDEXX Laboratories by 4.4% during the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 943,305 shares of the company’s stock worth $175,473,000 after buying an additional 40,046 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:IDXX traded down $3.45 on Friday, hitting $242.77. 4,281 shares of the company’s stock traded hands, compared to its average volume of 516,699. The company has a debt-to-equity ratio of 14.81, a current ratio of 1.01 and a quick ratio of 0.74. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $256.22. The stock has a market cap of $21.18 billion, a PE ratio of 56.79 and a beta of 0.97.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The company had revenue of $576.06 million for the quarter, compared to analysts’ expectations of $575.04 million. During the same quarter in the previous year, the business posted $1.01 EPS. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.8 earnings per share for the current year.

In other IDEXX Laboratories news, insider Giovani Twigge sold 2,015 shares of IDEXX Laboratories stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $250.00, for a total transaction of $503,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Jonathan W. Ayers sold 28,000 shares of IDEXX Laboratories stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $249.02, for a total value of $6,972,560.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,761 shares of company stock worth $14,196,458. Company insiders own 2.70% of the company’s stock.

Several research firms have issued reports on IDXX. Canaccord Genuity boosted their price objective on IDEXX Laboratories from $255.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, April 30th. Finally, Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective on the stock in a report on Friday, May 3rd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $253.50.

ILLEGAL ACTIVITY WARNING: This report was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/idexx-laboratories-inc-idxx-shares-bought-by-stephens-investment-management-group-llc.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: What is a Real Estate Investment Trust (REIT)?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.